Do Statins Lower CRP? What the Research Shows

For decades, statins were understood almost entirely through the lens of cholesterol. They block an enzyme the liver uses to make cholesterol, LDL levels fall, and cardiovascular risk drops. That story is true, but it turned out to be incomplete. Beginning in the early 2000s, researchers noticed that statins consistently lowered C-reactive protein, a blood marker of systemic inflammation, and that this drop did not track neatly with the drop in cholesterol. The observation opened one of the most productive lines of inquiry in modern cardiology and helped establish inflammation as a target worth measuring and treating in its own right.

How Statins Lower CRP

Statins do more than block cholesterol synthesis. The enzyme they inhibit, HMG-CoA reductase, sits at the top of a biochemical pathway that produces not only cholesterol but also a family of signaling molecules called isoprenoids. Those molecules help switch on inflammatory pathways inside cells, including in the immune cells and blood vessel lining involved in atherosclerosis. By throttling that pathway, statins appear to quiet inflammatory signaling more broadly, an effect researchers call pleiotropy, meaning benefits that extend beyond the drug's primary target.

The downstream result is less production of the signals that drive CRP. Because CRP is made by the liver largely in response to interleukin-6, anything that reduces inflammatory cytokine activity tends to lower CRP. A 2024 analysis of blood samples from the JUPITER trial, published in Arteriosclerosis, Thrombosis, and Vascular Biology, gave a detailed look at this pleiotropy: after one year of high-intensity statin therapy, participants showed higher levels of bioactive lipids with anti-inflammatory and antioxidant properties and lower levels of pro-inflammatory ones, a molecular pattern the authors said supports the anti-inflammatory effects of statins beyond LDL cholesterol reduction (Hoshi et al., 2024).

The JUPITER Trial: The Landmark Evidence

The single most influential study on statins and CRP is JUPITER. Published in The New England Journal of Medicine in 2008 and led by Paul Ridker of Brigham and Women's Hospital, the trial was built on a deliberately unusual premise. Instead of enrolling people with high cholesterol, it enrolled 17,802 apparently healthy adults whose LDL cholesterol was already below 130 mg/dL but whose hsCRP was elevated at 2.0 mg/L or higher. In other words, these were people whose main visible risk factor was inflammation, not cholesterol. Participants were randomized to rosuvastatin 20 mg daily or placebo.

The results were strong enough that the trial was stopped early. After a median follow-up of just 1.9 years, rosuvastatin had reduced LDL cholesterol by 50 percent and hsCRP by 37 percent, and it cut the risk of a first major cardiovascular event, a composite of heart attack, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death, by 44 percent, corresponding to a hazard ratio of 0.56 (Ridker et al., 2008). Because these participants started with low LDL, JUPITER offered some of the clearest evidence that treating people selected for elevated inflammation, rather than elevated cholesterol, could produce meaningful benefit.

JUPITER did not settle every question, and it is worth being precise about what it showed. The trial demonstrated that a statin reduced both CRP and cardiovascular events in people with elevated CRP, but because rosuvastatin lowers cholesterol and CRP simultaneously, JUPITER alone could not fully separate how much of the benefit came from each. It also reported a small increase in physician-reported diabetes in the rosuvastatin group, a finding that has since been studied extensively and is part of why statin decisions are individualized. What JUPITER did establish beyond much doubt is that hsCRP identifies people who benefit from therapy and that statins bring that marker down.

How Much Do Statins Lower CRP?

The magnitude of CRP reduction varies with the statin, the dose, and the person, but the effect is consistent and often sizable. A useful reference point comes from the REVERSAL trial, published in The New England Journal of Medicine in 2005, which compared moderate statin therapy (pravastatin 40 mg) with intensive therapy (atorvastatin 80 mg) in 502 patients with coronary disease. Across the group, the geometric mean CRP level fell from 2.9 to 2.3 mg/L over 18 months, and intensive therapy lowered CRP more than moderate therapy did (Nissen et al., 2005).

The more striking finding from REVERSAL was what the CRP reduction predicted. Using intravascular ultrasound to measure the progression of plaque inside coronary arteries, the researchers found that the decrease in CRP was independently and significantly correlated with slower atherosclerosis progression, even after adjusting for the reduction in LDL and other lipids. Patients who achieved larger reductions in both LDL and CRP had significantly slower disease progression than those with smaller reductions in both. This helped move CRP from a passive risk marker toward something clinicians could track as a treatment target.

Is the CRP Drop Independent of Cholesterol?

This is the question that gives the topic its scientific weight. If statins only lowered CRP as a side effect of lowering cholesterol, then CRP would add little beyond a standard lipid panel. But the evidence points the other way. In a review of the rationale behind JUPITER, published in the American Journal of Cardiology, Samia Mora and Paul Ridker summarized accumulating evidence that statins lower plasma hs-CRP in a manner largely independent of LDL cholesterol lowering, and noted that the hsCRP level achieved after starting a statin may be as important as the LDL level achieved (Mora and Ridker, 2005).

Two threads of evidence support this independence. First, within trials, the correlation between how much LDL falls and how much CRP falls is weak, which suggests the two responses are at least partly separate. Second, earlier analyses of statin trials such as CARE and AFCAPS/TexCAPS found that people with elevated CRP derived greater relative benefit from statins, hinting that the inflammatory pathway itself was being addressed. Taken together, these observations reframed the statin from a purely cholesterol drug into one that acts on two of the pillars of cardiovascular risk at once: lipids and inflammation.

What This Means If You Are Already on a Statin

For someone taking a statin, CRP can offer a second lens on how therapy is working. A standard lipid panel tells you what is happening to cholesterol, but it says nothing directly about inflammation. Because statins lower CRP through partly separate mechanisms, an hsCRP measurement can add information about the inflammatory side of the equation. Major clinical guidance reflects this dual view. The 2017 dyslipidemia guidelines from the American Association of Clinical Endocrinologists and the American College of Endocrinology, for example, support measuring inflammatory markers such as hsCRP to help stratify cardiovascular risk in appropriate patients (Jellinger et al., 2017).

None of this is a reason to self-adjust medication. The choice of whether to take a statin, which one, and at what dose depends on your overall risk profile, your other conditions, and a conversation with your clinician. CRP is one input among several, and a single reading can be thrown off by a recent infection, injury, or flare of another condition. The practical value of tracking CRP is in the trend over time, viewed alongside the rest of your clinical picture rather than in isolation.

Statins Are Not the Only Way to Lower CRP

The same inflammatory pathway that statins act on also responds to how you live. That matters because most people thinking about their CRP are not necessarily candidates for medication. Regular physical activity, losing excess weight, stopping smoking, improving sleep, and shifting toward a dietary pattern rich in vegetables, fiber, and unsaturated fats have all been associated with lower CRP in research. These levers work through overlapping mechanisms: less visceral fat means less inflammatory cytokine production, better sleep steadies the signaling that drives CRP, and a higher-quality diet reduces the metabolic stress that keeps low-grade inflammation simmering.

For many people, lifestyle and medication are complementary rather than competing. Someone on a statin still benefits from the lifestyle factors that independently lower inflammation, and someone not on a statin can still meaningfully influence their CRP through daily habits. The unifying idea is that CRP reflects a real biological process that responds to multiple inputs, which is exactly what makes it useful to watch. You can explore the non-pharmacological side of this in more depth in our guide on how to lower CRP naturally.

Tracking CRP Over Time

The research on statins and CRP carries a broader lesson: inflammation is a number worth following. JUPITER showed that CRP identifies people who benefit from action, and REVERSAL showed that watching CRP fall can foreshadow slower disease progression. For anyone interested in their long-term wellness, the takeaway is not that everyone needs a statin, but that a single inflammatory marker can carry real information about the direction your body is heading.

C-reactive protein is well suited to this kind of tracking because it responds to so many inputs, from body composition and exercise to sleep, diet, and yes, medication. Sensa is designed to make checking CRP simple, letting you measure it at home without a needle or a clinic visit, so a reading becomes a routine data point rather than a rare event. Watching whether your CRP holds low or drifts over months gives you feedback on whether the changes you are making, pharmacological or not, are moving the marker in the right direction. CRP is a general wellness marker rather than a diagnosis, so persistent or rising values, and any questions about statin therapy, are best discussed with a qualified healthcare provider.

Sources

• Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER). New England Journal of Medicine, 2008. pubmed.ncbi.nlm.nih.gov/18997196
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease (REVERSAL). New England Journal of Medicine, 2005. pubmed.ncbi.nlm.nih.gov/15635110
• Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention (JUPITER): Can C-reactive Protein Be Used to Target Statin Therapy in Primary Prevention? American Journal of Cardiology, 2005. pubmed.ncbi.nlm.nih.gov/16442935
• Hoshi RA, Alotaibi M, Liu Y, et al. One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. pubmed.ncbi.nlm.nih.gov/38841856
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. AACE and ACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017. pubmed.ncbi.nlm.nih.gov/28437620

Frequently Asked Questions

Do statins lower CRP?

Yes. Statins consistently lower C-reactive protein, a marker of inflammation. In the JUPITER trial, rosuvastatin 20 mg reduced high-sensitivity CRP by 37 percent while also lowering LDL cholesterol by 50 percent. Research suggests the CRP reduction is largely independent of the cholesterol reduction, which is why statins are described as having anti-inflammatory effects in addition to lipid-lowering ones.

How much do statins lower CRP?

The amount varies by statin, dose, and individual, but reductions are often substantial. JUPITER reported a 37 percent drop in hsCRP with rosuvastatin, and in the REVERSAL trial the geometric mean CRP fell from 2.9 to 2.3 mg/L, with intensive statin therapy lowering CRP more than moderate therapy. Higher-intensity statins tend to produce larger CRP reductions.

Is the CRP reduction from statins separate from the cholesterol effect?

Largely, yes. Within statin trials, the amount CRP falls correlates only weakly with the amount LDL cholesterol falls, and reviews of the evidence conclude that statins lower hsCRP in a manner largely independent of LDL lowering. Statins act on a biochemical pathway that produces inflammatory signaling molecules, not just cholesterol, which helps explain the separate anti-inflammatory effect.

Should I take a statin to lower my CRP?

That decision belongs with your healthcare provider and depends on your overall cardiovascular risk, not on CRP alone. Statins are prescription medications with benefits and considerations that are individualized. CRP is one input among several, and lifestyle factors such as exercise, weight, sleep, and diet also meaningfully influence it. Never start, stop, or change medication based on a single marker without medical guidance.